By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved Roche's drug and companion diagnostic test for late-stage unresectable melanoma.

The agency today approved Zelboraf (vemurafenib), co-developed with Daiichi Sankyo, for the treatment of patients with melanoma whose tumors express a gene mutation known as BRAF V600E. At the same time it approved the cobas 4800 BRAF V600 Mutation Test for determining whether a patient's melanoma cells have the mutation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.